Healthcare entity
All 1 tracked stories fall under one category: market-trends. Alnylam Pharmaceuticals is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 3 original sources on average. We currently track 1 Healthcare story that mention AMVUTTRA, all published on August 31, 2026.
Last mentioned: Aug 31, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: market-trends. Alnylam Pharmaceuticals is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 3 original sources on average. We currently track 1 Healthcare story that mention AMVUTTRA, all published on August 31, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 1 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering AMVUTTRA. Shared-story counts are live from our verified record — not editorial picks.
New ESC 2026 data suggest RNAi therapy vutrisiran provides consistent cardiovascular benefit in ATTR cardiomyopathy patients regardless of baseline tafamidis use, with implications for cardiology treatment pathways and broader hypertension management.
AMVUTTRA is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
